Drug Trial Radar · NCT07294118
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- The University of Texas Medical Branch, GalvestonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.
Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Headache
- Opiate Dependence
- Opioid Use
Interventions
LidocaineDrug
The participants will receive 50 mg of lidocaine.
Lidocaine and DexamethasoneDrug
The participants will receive 50 mg of lidocaine and 10 mg of dexamethasone one after the other.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Analog Scale (VAS) ScoreTime frame: Baseline
- Visual Analog Scale (VAS) ScoreTime frame: Every 4 hours for 24 hours following the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Medical Branch, Galveston
Galveston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.